Kind | Enrichment | KDVS |
|---|
Lists | PTvsM | PTvsN | PTvsM | PTvsM | PTvsN | PTvsN |
|---|
| | | | MF | BP | MF | BP |
|---|
Discr. GO Terms
| 60 | 120 | 1115 | 2242 | 320 | 689 |
Discr. Genes
| 59 | 389 | 3619 | 4457 | 3118 | 3271 |
Comm. GO Terms
| 27 | 61 | 375 | 1000 | 158 | 378 |
Comm. Genes
| 7 | 51 | 418 | 504 | 334 | 371 |
Bench. Cov. GO Terms
| 1% | 2% | 46% | 41% | 19% | 16% |
Bench. Cov. Genes
| 1% | 6% | 49% | 59% | 39% | 44% |
- In the first two rows, the table shows the discriminant gene and GO term lists identified by enrichment–based approach and KDVS for each classification problem solved: Primary Tumor (PT) versus Metastasis (M) and Primary Tumor vs Normal (N). For KDVS, in addition, each classification task was addressed two times, based on the GO domain utilized, Molecular Function (MF) or Biological Process (BP). Discr. stands for discriminant.
- In the next two rows, the table shows the gene and GO term lists obtained as an intersection between respective discriminant lists and benchmark lists, built for prostate cancer. Comm. means common.
- In the last two rows, the table shows the coverage of benchmark gene and GO term lists with respective discriminant lists. For KDVS, the coverage was calculated only for benchmark MF and BP terms, respectively, according to GO domain utilized in classification task. Benchmark gene list consists of 851 elements. Benchmark GO term list consists of 2437 BP terms and 824 MF terms, 3593 terms in total. Bench. cov. means benchmark coverage.
